In Brief: FDA considers emergency contraceptive label change, CRN points out FSMA exemptions; NAD refers Maxam claims to FTC
This article was originally published in The Tan Sheet
FDA considers emergency contraceptive label change; CRN points out FSMA exemptions; NAD refers Maxam claims to FTC; P&G executives retire; nutritional product firms among top direct sellers; Boots recalls store brand products; more In Brief.
You may also be interested in...
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Abingdon Health has announced that a study run in conjunction with the UK Rapid Test Consortium has demonstrated that its AbC-19 test could be an effective tool for testing vaccine efficacy.
NGO says the Expert Panel for Cosmetic Ingredient Safety’s conclusion on methylisothiazolinone in 2020 was among decisions “not in the interest of public health.” However, other assessments highlighted by the group suggest that the Cosmetic Ingredient Review is working as an open forum for public input and discussion.